SEC Form 4 · accession 0001209191-16-111822
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Charles Bramlage
Director
Period of report
Mar 28, 2016
Accepted (ET)
Apr 1, 2016 · 7:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $15.75 | Mar 28, 2016 | A | 25,000 | A | — | Mar 28, 2026 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The option vests in equal monthly installments over 12 months measured from March 28, 2016 subject to Reporting Person's continuous service status as of each such date.
- F2The option is subject to shareholder approval of an amendment to the Celladon Corporation 2013 Equity Incentive Plan. This is a voluntary early filing.